Iodine-129 microdosing for protein and peptide drug development: Erythropoietin as a case study

Bioanalysis

Volumn 5, Issue 1, 2013, Pages 53-63

  Lamers, Robert Jan A N ^a,b   De Jong, Arie F M ^b   López Gutiérrez, José M ^c   Gomez Guzman J M ^c  

^a Abundnz BV   (Netherlands)

^b Ducares BV   (Netherlands)

^c CENTRO NACIONAL DE ACELERADORES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 129; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ARTICLE; CASE STUDY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG LABELING; DRUG MICRODOSE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MICRODOSIMETRY; NONHUMAN; RADIOIODINATION; RAT; SURFACE PLASMON RESONANCE;

ACCELERATION; ANIMALS; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; ERYTHROPOIETIN; FEASIBILITY STUDIES; HALF-LIFE; HUMANS; IODINE ISOTOPES; MALE; MASS SPECTROMETRY; RATS; RATS, WISTAR; SURFACE PLASMON RESONANCE;

EID: 84871544301     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.297     Document Type: Article

References (45)

1. Tuniz C, Bird JR, Fink D et al. Accelerator Mass Spectrometry, Ultrasensitive Analysis for Global Science. CRC Press, Boca Raton, FL, USA (1998).
2. Turteltaub KW, Felton JS, Gledhill BL et al. Accelerator mass spectrometry in biomedical dosimetry: Relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc. Natl Acad. Sci. USA 87(14), 5288-5292 (1990).
3. Turteltaub KW, Vogel JS. Bioanalytical applications of accelerator mass spectrometry for pharmaceutical research. Curr. Pharm. Des. 6(10), 991-1007 (2000).
4. Turteltaub KW, Frantz CE, Creek MR et al. DNA adducts in model systems and humans. J. Cell. Biochem. Suppl. 17F, 138-148 (1993).
5. Turteltaub KW, Dingley KH, Curtis KD et al. Macromolecular adduct formation and metabolism of heterocyclic amines in humans and rodents at low doses. Cancer Lett. 143(2), 149-155 (1999).
6. Turteltaub KW, Dingley KH. Application of accelerated mass spectrometry (AMS) in DNA adduct quantification and identification. Toxicol. Lett. 102-103, 435-439 (1998).
7. Duecker SR, Vuong LT, Lohstroh PN et al. Quantifying exploratory low dose compounds in humans with AMS. Adv. Drug Deliv. Rev. 63(7), 518-531 (2011).
8. Lappin G, Garner RC. Big physics, small doses: The use of AMS and PET in human microdosing of development drugs. Nat. Rev. Drug Discov. 2(3), 233-240 (2003).
9. Garner R. Accelerator mass spectrometry in pharmaceutical research and development Y a new ultrasensitive analytical method for isotope measurement. Curr. Drug Metab. 1(2), 205-213 (2000).
10. Lappin G, Garner RC. Current perspectives of 14C-isotope measurements in biomedical accelerator mass spectrometry. Anal. Bioanal. Chem. 378(2), 356-364 (2004).
11. Lappin G, Shishikura R, Jochemsen R et al. Pharmacokinetics of fexofenadine: Evaluation of a microdose and assessment of absolute oral bioavailability. Eur. J. Pharm. Sci. 40(2), 125-131 (2010).
12. Vuong L, Blood A, Vogel J et al. Applications of accelerator MS in pediatric drug evaluation. Bioanalysis 4(15), 1871-1882 (2012).
13. Ieiri I, Fukae M, Maeda K et al. Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPS and OATPs following oral microdosing. Int. J. Clin. Pharmacol. Ther. 50(10), 689-700 (2012).
14. Park MK, Shin KH, Kim KP et al. Open label, three period, single sequence, study of, 25, 50 mg sertraline pharmacokinetics in healthy male Korean volunteers. Int. J. Clin. Pharmacol. Ther. 49(11), 672-678 (2011).
15. Henderson PT, Li T, He M et al. A microdosing approach for characterizing formation and repair of carboplatinYDNA monoadducts and chemoresistance. Int. J. Cancer 129(6), 1425-1434 (2011).
16. Lappin G. Microdosing: Current and the future. Bioanalysis 2(3), 509-517 (2010).
17. Garner RC. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data. Bioanalysis 2(3), 429-440 (2010).
18. Jekunen AP, Pauwels EK, Kairemo KJ. Microdosing in early lead discovery. Bioanalysis 2(3), 421-428 (2010).
19. Tozuka Z, Kusuhara H, Nozawa K et al. Microdose study of 14C-acetaminophen with accelerator mass spectrometry to examine pharmacokinetics of parent drug and metabolites in healthy subjects. Clin. Pharmacol. Ther. 88(6), 824-830 (2010).
20. Gao L, Li J, Kasserra C et al. Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: Application in microdose absolute bioavailability studies. Anal. Chem. 83(14), 5607-5616 (2011).
21. Ings R. Microdosing: A valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge. Bioanalysis 1(7), 1293-1305 (2009).
22. Lappin G, Garner C. The utility of microdosing over the past 5 years. Expert Opin. Drug Metab. Toxicol. 4(12), 1499-1506 (2008).
23. Bonate PL, Howard DR. Pharmacokinetics in Drug Development. Springer, New York, NY, USA, 120-121 (2011).
24. Rowland M. Microdosing and the 3Rs. National Centre for the Replacement, Refinement and Reduction of Animals in Research, London, UK, 1-7 (2006).
25. Bertino JS Jr, Greenberg HE, Reed MD et al. American college of clinical pharmacology position statement on the use of microdosing in the drug development process. J. Clin. Pharmacol. 47(4), 418-422 (2007).
26. US FDA, Department of Health and Human Services. Guidelines for Industry Investigators and Reviewers: Exploratory IND Studies. FDA, Rockville, MD, USA (2006).
27. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. European Medicines Agency, London, UK (2009).
28. Lappin G, Garner RC, Meyers T et al. Novel use of accelerator mass spectrometry for the quantification of low levels of systemic therapeutic recombinant protein. J. Pharm. Biomed. Anal. 41(4), 1299-1302 (2006).
29. Salehpour M, Ekblom J, Sabetsky V et al. Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals. Rapid Commun. Mass Spectrom. 24(10), 1481-1489 (2010).
30. Gélinas Y, Krushevska A, Barnes RM. Determination of total iodine in nutritional and biological samples by ICP-MS following their combustion within an oxygen stream. Anal. Chem. 70(5) 1021-1025 (1998).
31. Eisenbud M, Gesell TF. Environmental Radioactivity: From Natural, Industrial and Military Sources. Academic Press, San Diego, CA, USA, 656 (1997).
32. National Council on Radiation Protection and Measurement. Iodine-129: Evaluation of Releases from Nuclear Power Generation. National Council on Radiation Protection and Measurement, Bethesda, MD, USA (1983).
33. Kilius LR, Litherland AE, Rucklidge JC et al. Accelerator mass-spectrometry measurements of heavy long-lived isotopes. Int. J. Rad. Appl. Instrum. A 43(1-2), 279-287 (1992).
34. Fabryka-Martin J, Bentley H, Elmore D, Airey PL. Natural iodine-129 as an environmental tracer. Geochim. Cosmochim. Acta 49(2), 337-347 (1985).
35. Hou X, Malencheko AF, Kucera J et al. Iodine-129 in thyroid and urine in Ukraine and Denmark. Sci. Total Envir. 302(1-3), 63-73 (2003).
36. Bailey GS. Labeling of peptides and proteins by radioiodination. Methods Mol. Biol. 32, 441-448 (1994).
37. Leader B, Baca Q J, Golan DE. Protein therapeutics: A summary and pharmacological classification. Nat. Rev. Drug Discov. 7(1), 21-39 (2008).
38. Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human erythropoietin gene. Proc. Natl Acad. Sci. USA 82(22), 7580-7584 (1985).
39. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 316(2), 73-78 (1987).
40. Liedberg B, Nylander C, Lundstrom I. Surface plasmon resonance for gas detection and biosensing. Sens. Actuators 4, 299-304 (1983).
41. Glemser O, Saur H. "Silver Iodide" in Handbook of Preparative Inorganic Chemistry. Academic Press, New York, NY, USA, 1036-1037 (1963).
42. Gómez-Guzmán JM, López-Gutiérrez, Holm E et al. 129I measurements on the 1MV AMS facility at the Centro Nacional de Aceleradores (CNA, Spain). Appl. Rad. Isot. 70(1), 263-268 (2012).
43. Kato M, Kamiyama H, Okazaki A et al. Mechanism for the nonlinear pharmacokinetics of Erytropoietin in rats. J. Pharmacol. Exp. Ther. 283(2), 520-527 (1997).
44. Emmanouel DS, Goldwasser E, Katz AI. Metabolism of pure human erythropoietin in the rat. Am. J. Physiol. 247(1 Pt 2), F168-F176 (1984).
45. Parnham MJ, Schindler-Horvat J, Kozlovic M. Non-clinical safety studies on biosimilar recombinant human erythropoeitin. Basic Clin. Pharmacol. Toxicol. 100(2), 73-83 (2007).